Pratley R - Search Results

1

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.

White WB, Pratley R, Fleck P, Munsaka M, Hisada M, Wilson C, Menon V. White WB, et al. Among authors: pratley r. Diabetes Obes Metab. 2013 Jul;15(7):668-73. doi: 10.1111/dom.12093. Epub 2013 Apr 4. Diabetes Obes Metab. 2013. PMID: 23489301 Clinical Trial.

2

Relation of the white blood cell count to obesity and insulin resistance: effect of race and gender.

Pratley RE, Wilson C, Bogardus C. Pratley RE, et al. Obes Res. 1995 Nov;3(6):563-71. doi: 10.1002/j.1550-8528.1995.tb00191.x. Obes Res. 1995. PMID: 8653533 Free article.

3

Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes.

Gautier JF, Wilson C, Weyer C, Mott D, Knowler WC, Cavaghan M, Polonsky KS, Bogardus C, Pratley RE. Gautier JF, et al. Among authors: pratley re. Diabetes. 2001 Aug;50(8):1828-33. doi: 10.2337/diabetes.50.8.1828. Diabetes. 2001. PMID: 11473045

4

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE. D'Alessio DA, et al. J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. doi: 10.1210/jc.2008-1135. Epub 2008 Oct 28. J Clin Endocrinol Metab. 2009. PMID: 18957505 Free PMC article. Clinical Trial.

5

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.

Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group. Pratley RE, et al. Diabetes Obes Metab. 2009 Feb;11(2):167-76. doi: 10.1111/j.1463-1326.2008.01016.x. Diabetes Obes Metab. 2009. PMID: 19125778 Clinical Trial.

6

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

Pratley RE. Pratley RE. Expert Opin Pharmacother. 2009 Feb;10(3):503-12. doi: 10.1517/14656560802694713. Expert Opin Pharmacother. 2009. PMID: 19191685 Review.

7

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group. Pratley RE, et al. Curr Med Res Opin. 2009 Oct;25(10):2361-71. doi: 10.1185/03007990903156111. Curr Med Res Opin. 2009. PMID: 19650752 Clinical Trial.

8

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.

Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Pratley RE, et al. J Am Geriatr Soc. 2009 Nov;57(11):2011-9. doi: 10.1111/j.1532-5415.2009.02484.x. Epub 2009 Sep 30. J Am Geriatr Soc. 2009. PMID: 19793357

9

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. DeFronzo RA, et al. Among authors: pratley re. J Clin Endocrinol Metab. 2012 May;97(5):1615-22. doi: 10.1210/jc.2011-2243. Epub 2012 Mar 14. J Clin Endocrinol Metab. 2012. PMID: 22419732 Clinical Trial.

10

Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).

Pratley RE, Urosevic D, Boldrin M, Balena R; T-emerge 6 Study Group. Pratley RE, et al. Diabetes Obes Metab. 2013 Mar;15(3):234-40. doi: 10.1111/dom.12009. Epub 2012 Sep 30. Diabetes Obes Metab. 2013. PMID: 22958426 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

467 results

Search Page

Filters